Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.

Bronsky J, Copova I, Kazeka D, Lerchova T, Mitrova K, Pospisilova K, Sulovcova M, Zarubova K, Hradsky O

DOI: 10.14309/ctg.0000000000000490
Published: 2022 May 1
Container: Clinical and translational gastroenterology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.14309/ctg.0000000000000490,
  title = {Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.},
  author = {Bronsky J and Copova I and Kazeka D and Lerchova T and Mitrova K and Pospisilova K and Sulovcova M and Zarubova K and Hradsky O},
  year = {2022},
  journal = {Clinical and translational gastroenterology},
  doi = {10.14309/ctg.0000000000000490},
  url = {https://doi.org/10.14309/ctg.0000000000000490}
}

RIS

TY  - JOUR
TI  - Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.
AU  - Bronsky J
AU  - Copova I
AU  - Kazeka D
AU  - Lerchova T
AU  - Mitrova K
AU  - Pospisilova K
AU  - Sulovcova M
AU  - Zarubova K
AU  - Hradsky O
PY  - 2022
JO  - Clinical and translational gastroenterology
DO  - 10.14309/ctg.0000000000000490
UR  - https://doi.org/10.14309/ctg.0000000000000490
ER  -

APA

J, B., I, C., D, K., T, L., K, M., K, P., M, S., K, Z., & O, H. (2022). Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation.. Clinical and translational gastroenterology. https://doi.org/10.14309/ctg.0000000000000490

Source records

pubmed · retrieved 2026-09-27T11:05:12.099Z
europe-pmc · retrieved 2026-09-27T11:05:12.102Z